Table 6.
Clinical and laboratory results of patients by steroid use at presentation
| All steroids (n = 62) | All no steroids (n = 80) | P value | IC-MPGN steroids (n = 28) | IC-MPGN no steroids (n = 13) | P value | C3G steroids (n = 24) | C3G no steroids (n = 19) | P value | |
|---|---|---|---|---|---|---|---|---|---|
| eGFR at diagnosis (ml/min per 1.73 m2) | 71.4 (61.1–81.6) | 69.1 (53.4–84.8) | NS (0.8054) | 76.8 (62.2–91.4) | 71.7 (31.3–112.0) | NS (0.7580) | 62.6 (43.8–81.4) | 115.6 (97.4–134.0) | 0.0002a |
| eGFR at last follow-up (ml/min per 1.73 m2) | 87.2 (76.9–97.5) | 88.0 (74.7–101.4) | NS (0.9212) | 92.4 (77.9–106.9) | 102.6 (81.8–123.5) | NS (0.4611) | 101.6 (78.7–124.5) | 106.2 (84.6–127.8) | NS (0.7699) |
| Delta eGFR (ml/min per 1.73 m2) | 18.4 (6.1–30.8) | 21.5 (5.5–37.5) | NS (0.7616) | 15.6 (−1.8 to 32.9) | 34.1 (−16.8 to 85.1) | NS (0.3469) | 43.0 (12.9–73.0) | −3.0 (−23.1 to 17.2) | 0.0197a |
| C3 at diagnosis (g/l) | 0.34 (0.25– 0.42) | 0.49 (0.39–0.58) | 0.0224a | 0.34 (0.210–0.46) | 0.37 (−0.011 to 0.82) | NS (0.8443) | 0.33 (0.13–0.54) | 0.45 (0.22–0.69) | NS (0.4072) |
| C3 at last follow-up (g/l) | 0.57 (0.42–0.72) | 0.74 (0.59–0.88) | NS (0.1038) | 0.34 (0.14–0.55) | 0.82 (0.45–1.2) | 0.0165a | 0.78 (0.57–0.98) | 0.74 (0.44–1.0) | NS (0.8093) |
| Urine protein/creatinine ratio at diagnosis (mg/mmol) | 494.1 (261.8–726.5) | 373.1 (84.7–661.4) | NS (0.5149) | 534.9 (220.1–849.6) | 254.0 (−43.4 to 551.5) | NS (0.2665) | 518.4 (162.5–874.4) | 161.0 (27.0–295.0) | NS (0.0785) |
| Urine protein/creatinine ratio at last follow-up (mg/mmol) | 135.4 (78.0–192.8) | 314.4 (25.8–603.0) | NS (0.2049) | 239.9 (65.6–414.2) | 80.0 (0.59–159.4) | NS (0.2768) | 104.8 (43.5–166.2 | 131.9 (39.4–224.4) | NS (0.5898) |
| Hypertension at diagnosis | 66.1% | 42.5% | 0.0067a | 67.9% | 30.8% | 0.0425a | 58.3% | 27.8% | NS (0.0653) |
| Hypertension at last follow-up | 81.0% | 59.5% | 0.0479a | 85.0% | 16.7% | 0.0045a | 66.7% | 50% | NS (0.6570) |
| On antihypertensives at diagnosis | 82.3% | 36.2% | <0.0001a | 82.1% | 85.7% | NS (>0.9999) | 69.6% | 70.8% | NS (>0.9999) |
| On antihypertensives at last follow-up | 77.4% | 55.0% | 0.0076a | 46.2% | 38.5% | NS (>0.9999) | 16.7% | 77.8% | 0.0006a |
| Antihypertensives per patient at diagnosis | 2.4 (2.0–2.8) | 2.4 (1.9–2.8) | NS (0.9980) | 2.3 (1.6–3.1) | 1.6 (0.81–2.5) | NS (0.3661) | 2.1 (1.4–2.8) | 0.5 (−0.13 to 1.1) | 0.0048a |
| Antihypertensives per patient at last follow-up | 1.9 (1.5–2.3) | 1.8 (1.5–2.2) | NS (0.8485) | 1.9 (1.4–2.4) | 1.0 (1.0–1.0) | NS (0.1284) | 1.7 (0.9–2.5) | 1.0 (0.6–1.4) | NS (0.0769) |
C3, serum C3 level (reference range 0.83–1.52 g/l); C3G, C3 glomerulopathy; eGFR, estimated glomerular filtration rate based on bedside Schwartz formula; Cr, serum creatinine; IC-MPGN, immune-complex membranoproliferative glomerulonephritis; NS, not significant.
Numeric data shown the mean with 95% confidence interval.
a
Statistically significant.